Major histocompatibility complex class I molecules presenting HIV-1 envelope glycoprotein-derived peptides (MHC-I/HIV-1 Env)

Major histocompatibility complex class I (MHC-I) molecules presenting HIV-1 envelope glycoprotein (Env)-derived peptides are specialized protein complexes that signal the presence of viral infection to the immune system (UniProt, 2023). These complexes are formed when intracellular HIV-1 Env proteins, such as gp120 and gp41, are degraded by the proteasome into short peptides, which are then transported into the endoplasmic reticulum and loaded onto MHC-I molecules for surface expression (NIH/NCBI, 2022). Recognition of these peptide-MHC (pMHC) complexes by the T-cell receptors (TCRs) of CD8+ cytotoxic T lymphocytes is a fundamental step in the cellular immune response against HIV-1 (PubMed, 2021). In therapeutic contexts, these complexes are targeted by advanced modalities like TCR-engineered T cells and bispecific T-cell engagers, such as ImmTAVs, to enhance the clearance of the viral reservoir (Immunocore, 2023). A significant challenge in targeting HIV-1 Env peptides is the high genetic diversity and rapid mutation rate of the envelope gene, which allows the virus to escape immune detection by altering the targeted epitopes (Journal of Virology, 2020). Consequently, drug development focuses on identifying highly conserved Env epitopes across different viral clades to ensure broad therapeutic applicability (Frontiers in Immunology, 2021).

Other names

HLA-I/HIV-1 Env peptide complexpMHC-I (HIV-1 Env)MHC-I/gp120 complexMHC-I/gp41 complexHuman leukocyte antigen class I presenting HIV-1 Env peptides

Redirection of cytotoxic T lymphocytes to recognize and lyse HIV-infected cells through specific binding to the peptide-MHC complex.